General Clinical Chemistry Analyzers and Accessories
Abcam E7820, 5MG
MW 336.4 Da, Purity >=98%. A small molecule sulfonamide derivative with potential antiangiogenic and antitumor activities. E7820 inhibits angiogenesis by suppressing integrin alpha 2, a cell adhesion molecule expressed on endothelial cells. Inhibition of integrin alpha 2 leads to an inhibition of cell-cell interactions, endothelial cell-matrix interactions, vascular endothelial cell proliferation and angiogenesis.
The product is subject to the following: Abcam Restricted Use Statement
Abcam E7820, 25MG
MW 336.4 Da, Purity >=98%. A small molecule sulfonamide derivative with potential antiangiogenic and antitumor activities. E7820 inhibits angiogenesis by suppressing integrin alpha 2, a cell adhesion molecule expressed on endothelial cells. Inhibition of integrin alpha 2 leads to an inhibition of cell-cell interactions, endothelial cell-matrix interactions, vascular endothelial cell proliferation and angiogenesis.
The product is subject to the following: Abcam Restricted Use Statement
Abcam ML-385, 5MG
MW 511.6 Da, Purity >=98%. A potent and selective Nrf2 inhibitor (Nrf2; IC₅₀ = 1.9 μM). ML-385 blocks Nrf2 downstream target gene expression. ML-385 displays specificity and selectivity for NSCLC cells with KEAP1 mutation, which leads to gain of Nrf2 function.
The product is subject to the following: Abcam Restricted Use Statement
Abcam V-9302, 1MG
MW 538.7 Da, Purity >=98%. A competitive antagonist of transmembrane glutamine flux, that selectively targets the amino acid transporter ASCT2 (SLC1A5). V-9302 inhibits ASCT2-mediated glutamine uptake (IC₅₀ = 9.6 μM) in HEK-293 cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam V-9302, 5MG
MW 538.7 Da, Purity >=98%. A competitive antagonist of transmembrane glutamine flux, that selectively targets the amino acid transporter ASCT2 (SLC1A5). V-9302 inhibits ASCT2-mediated glutamine uptake (IC₅₀ = 9.6 μM) in HEK-293 cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam AZD-5069, 25MG
MW 476.5 Da, Purity >=98%. A potent and reversible CXCR2 chemokine receptor antagonist with potential anti-inflammatory and antineoplastic activities. Upon administration, CXC chemokine receptor 2 antagonist AZD5069 directly binds to CXCR2 and inhibits its activation. This inhibits CXCR2-mediated signaling and may inhibit tumor cell proliferation in CXCR2-overexpressing tumor cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GW-311616A, 5MG
MW 434 Da, Purity >=98%. A potent and selective intracellular neutrophil elastase (NE, alpha-1-proteinase) inhibitor. Inhibits human neutrophil elastase (HNE) and is selective over other human serine proteases with IC₅₀ values of 22 nM for HNE, >100 μM for trypsin, cathepsin G and plasmin, >3 μM for chymotrypsin and tissue plasminogen activator.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GSK2656157, 5MG
MW 416.5 Da, Purity >=98%. Potent and selective PERK inhibitor (IC₅₀ = 0.9 nM in cell-free assay). ATP-competitive. Exibits 500-fold selectivity for PERK versus a panel of 300 kinases.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ganetespib (STA-9090), 5MG
MW 364.4 Da, Purity >98%. Potent Hsp90 inhibitor (IC₅₀ of 4nM in OSA 8 cells). Causes cytotoxicity in a variety of hematological and solid tumor cell lines by causing degradation of multiple oncogenic Hsp90 client proteins. Ganetespib inhibits MG63 cell lines with IC₅₀ of 43 nM.
The product is subject to the following: Abcam Restricted Use Statement
Abcam PF-573228, 10MG
MW 491.5 Da, Purity >=98%. Potent and selective FAK inhibitor (IC₅₀ = 4 nM versus recombunant catalytic fragent). Blocks FAK Tyr397phosphorylation in cultured cells (IC₅₀ = 30–100 nM). Shows 50 - 250-fold selectivity for FAK aginst a panel of 40 recombinant kinases. Inhibits chemotactic and haptotactic cell migration.
The product is subject to the following: Abcam Restricted Use Statement
Abcam GSK2656157, 25MG
MW 416.5 Da, Purity >=98%. Potent and selective PERK inhibitor (IC₅₀ = 0.9 nM in cell-free assay). ATP-competitive. Exibits 500-fold selectivity for PERK versus a panel of 300 kinases.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LY2940680 (Taladegib), 10MG
MW 512.5 Da. Potent Hedgehog signaling pathway inhibitor. Smoothened antagonist. Inhibits growth of cancer cell lines containing a disease-relevant Smoothened gene mutation. Has anti-tumor activity in animal models.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Sonidegib (NVP-LDE225, Erismodegib), smoothened (Smo) antagonist, 10MG
MW 485.5 Da. Potent and selective Smoothened antagonist. Blocks Hedgehog signaling pathway activity (IC₅₀ = 1.3 nM (mouse) and 2.5 nM (human) in cell-free assays. Anti-tumor activity in mouse medulloblastoma allograft model.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LY2940680 (Taladegib), 5MG
MW 512.5 Da. Potent Hedgehog signaling pathway inhibitor. Smoothened antagonist. Inhibits growth of cancer cell lines containing a disease-relevant Smoothened gene mutation. Has anti-tumor activity in animal models.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SP-2509, LSD1 inhibitor, 5MG
MW 437.9 Da, Purity >98%. Potent, selective (IC₅₀ = 13 nM) and reversible inhibitor of the histone demethylase LSD1 (KDM1A). No activity against MAO-A, MAO-B, lactate dehydrogenase and glucose oxidase.
The product is subject to the following: Abcam Restricted Use Statement